Psychedelic News and Analysis Made Simple for Investors

Psychedelic Invest is a resource for those looking to invest in the burgeoning psychedelic industry.

Track the entire psychedelic market

Track the entire psychedelic market

We’ve developed the first all encompassing index to track the public psychedelic marketplace.

Explore the Index

Just Some of the Data we Cover

Latest News

Press

Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights

Highlights: 6-week top-line data from Part A of COMP005 phase 3 trial in treatment resistant depression on track for late June Phase 3 COMP006 in TRD on track for 26-week data second half of 2026 Cash position of $260.1 million at March 31, 2025 Conference call on May 8 at 8:00 am ET (1:00 pm…

Press Release Press

MindBio Issues Restricted Stock Units

Vancouver, British Columbia –TheNewswire –May 7, 2025– MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (“MindBio”), (the “Company”), a pioneering clinical-stage biopharmaceutical company dedicated to developing novel and effective mental health treatments, has today issued Restricted Stock Units (RSUs) to certain directors and individuals that work for the Company. On May 2, 2025, the Company’s Board of Directors approved the issuance…

Optimi-Health Press

Optimi Health Obtains U.S. FDA Drug Establishment Registration

Vancouver, British Columbia–(Newsfile Corp. – May 5, 2025) – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company“), a manufacturer of GMP-certified MDMA and psilocybin, has received its U.S. FDA Establishment Identifier (FEI) number—a key regulatory step for engaging in FDA filings and compliant supply into the United States. According to…

Mydecine Innovations Group Press

Mydecine Innovations Group Provides Update on Annual Financial Statements

Vancouver, British Columbia – TheNewswire – May 15, 2025 — Mydecine Innovations Group Inc. (the “Company”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) is providing this update on the status of a management cease trade order granted on May 1, 2025 (the “MCTO”) by the British Columbia Securities Commission under National Policy 12-203 – Management Cease…

Psyence Press

Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split

New York, New York–(Newsfile Corp. – May 1, 2025) – Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence BioMed” or the “Company”) today announced the effective date of its 1-for-7.97 share consolidation (reverse stock split) of the Company’s issued and outstanding common shares. At a Special Meeting of Stockholders held on April 16, 2025, shareholders approved a…

Cybin Press

Cybin to Participate at the 28th Annual Milken Institute Global Conference

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that Doug Drysdale, Cybin’s Chief Executive Officer, will be speaking at the 28th Annual Milken Institute Global Conference on a panel entitled “The Global Landscape…

Silo Pharma Press

Silo Pharma’s SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study

SARASOTA, FL, April 30, 2025 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo,” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced positive results for its preclinical study evaluating SP-26, a novel extended-release ketamine implant which it believes supports SP-26’s potential as a safe, well-tolerated,…

Explore the Psychedelic Landscape

Learn more about the psychedelic companies changing the industry.